Welch Allyn's portable ECG launches
This article was originally published in Clinica
Welch Allyn is to address the telehealth market with the launch of a portable connectivity-ready electrocardiograph (ECG). The lightweight device, called the CP 50 ECG, is designed for use in settings where flexibility and efficiency are important. It can interface with the Welch Allyn CardioPerfect Workstation Software to connect patient data to electronic health records or a health information system, over the internet or through e-mail. The device comes with an integrated high-resolution thermal printer to generate ECG reports in customisable formats, and it also allows paperless archiving and flexible connectivity options. In addition, the CP 50 provides on-screen instructions that ensure accurate data capture by highlighting poor signals and connections. Welch Allyn said it is addressing the "growing demand" for products with greater efficiency and more connectivity options to move healthcare delivery beyond traditional approaches. The product is scheduled for worldwide release in the coming months, the Skaneateles Falls, New York firm said.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.